Literature DB >> 1721841

Granulocyte colony-stimulating factor (G-CSF) treatment in a neutropenic leukemia patient with diffuse interstitial pulmonary infiltrates.

A Heyll1, C Aul, F Gogolin, M Thomas, M Arning, A Gehrt, U Hadding.   

Abstract

Adult respiratory distress syndrome (ARDS) in patients suffering from acute leukemia usually occurs during chemotherapy-induced neutropenia. In addition, intensified chemotherapy with high-dose cytosine arabinoside and mediastinal irradiation may contribute to the development of ARDS. This complication is usually refractory to conservative treatment with antibiotics, steroids, and mechanical ventilation. In this report, we describe a 25-year-old patient with acute lymphoblastic leukemia who developed ARDS during the phase of chemotherapy-induced neutropenia. Subcutaneous administration of granulocyte colony-stimulating factor (G-CSF) at doses of 300-600 micrograms/day led to a prompt increase of peripheral granulocyte counts. With resolution of neutropenia, respiratory function gradually improved, and mechanical ventilatory support was stopped after 2 weeks. From this observation we surmise that the application of G-CSF may be an effective therapeutic approach for preventing the fatal outcome of ARDS in leukemia patients with bone marrow aplasia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721841     DOI: 10.1007/bf01709656

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  17 in total

1.  Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.

Authors:  L M Souza; T C Boone; J Gabrilove; P H Lai; K M Zsebo; D C Murdock; V R Chazin; J Bruszewski; H Lu; K K Chen; J Barendt; E Platzer; M A S Moore; R Mertelsmann; K Welte
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

2.  Binding characteristics and proliferative action of purified granulocyte colony-stimulating factor (G-CSF) on normal and leukemic human promyelocytes.

Authors:  C G Begley; D Metcalf; N A Nicola
Journal:  Exp Hematol       Date:  1988-01       Impact factor: 3.084

3.  Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.

Authors:  D Hoelzer; E Thiel; H Löffler; T Büchner; A Ganser; G Heil; P Koch; M Freund; H Diedrich; H Rühl
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

4.  Side effects of intermediate- and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute leukaemia and non-Hodgkin's lymphoma.

Authors:  W G Peters; R Willemze; L P Colly; H F Guiot
Journal:  Neth J Med       Date:  1987-02       Impact factor: 1.422

5.  Adult respiratory distress syndrome in patients with severe neutropenia.

Authors:  F P Ognibene; S E Martin; M M Parker; T Schlesinger; P Roach; C Burch; J H Shelhamer; J E Parrillo
Journal:  N Engl J Med       Date:  1986-08-28       Impact factor: 91.245

6.  Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  W P Sheridan; G Morstyn; M Wolf; A Dodds; J Lusk; D Maher; J E Layton; M D Green; L Souza; R M Fox
Journal:  Lancet       Date:  1989-10-14       Impact factor: 79.321

7.  Adult respiratory distress syndrome in neutropenic leukemia patients.

Authors:  J F Vansteenkiste; M A Boogaerts
Journal:  Blut       Date:  1989-06

8.  The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients.

Authors:  J G Villablanca; M Steiner; J Kersey; N K Ramsay; P Ferrieri; R Haake; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  1990-06       Impact factor: 5.483

9.  Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin.

Authors:  H F Guiot; W G Peters; P J van den Broek; J W van der Meer; J A Kramps; R Willemze; R van Furth
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

10.  High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.

Authors:  R J Jones; S Piantadosi; R B Mann; R F Ambinder; E J Seifter; H M Vriesendorp; M D Abeloff; W H Burns; W S May; S D Rowley
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.